Company: CDT
Filing Date: 2025-07-08
Form Type: DEF 14A
Source: 0001641172-25-018242
Chunk: 51

Company: CDT Equity Inc.
Filing Date: 2025-07-08
Form: DEF 14A
Chunk 51
---
 |

<div align='center'>PROPOSAL NO. 3 – Approval of an increase in the number of shares issuable pursuant to the 2023 Plan, IN THE FORM ATTACHED AS ANNEX A TO THIS PROXY STATEMENT.</div>

On July 8, 2025, upon recommendation by the Compensation Committee, the Board approved and adopted, subject to the approval of the Company’s stockholders at the 2025 Annual Meeting, the amendment and restatement of the Conduit Pharmaceuticals Inc. 2023 Stock Incentive Plan. In this proposal, we refer to the original Conduit Pharmaceuticals Inc. 2023 Stock Incentive Plan as the “2023 Plan,” and we refer to the amended and restated Conduit Pharmaceuticals Inc. 2023 Stock Incentive Plan as the “Amended 2023 Plan.”

If approved by our stockholders, the amendment would authorize an additional 2,000,000 shares of common stock for awards under the Amended 2023 Plan, with such amount subject to adjustment for certain corporate events and under the applicable share counting rules, provided that, as of any date of grant, the total number of shares granted as awards under the Amended 2023 Plan, in the aggregate cannot exceed the shares available under the plan, and in addition, as of such grant date, such grant(s) cannot exceed 25% of our then total outstanding shares. In other words, as of any grant date, such shares granted under the Amended 2023 Plan in the aggregate, cannot be greater than 25% of the then total outstanding shares as of the grant date

The Company’s stockholders previously approved the 2023 Plan on September 22, 2023. The 2023 Plan affords the Compensation Committee the ability to design compensatory awards that are responsive to the Company’s needs and includes authorization for a variety of awards designed to advance the interests and long-term success of the Company by encouraging stock ownership among officers and other employees of the Company and its subsidiaries, certain consultants and other service providers to the Company and its subsidiaries, and non-employee directors of the Company. You are being asked to approve the Amended 2023 Plan.

The Board unanimously recommends that you vote to approve the Amended 2023 Plan. If the Amended 2023 Plan is approved by our stockholders at the 2025 Annual Meeting, it will be effective as of the day of the 2025 Annual Meeting, and future grants will be